8-K: Zyversa Therapeutics Faces Imminent Nasdaq Delisting Threat; Company to Appeal Non-Compliance Ruling

Zyversa Therapeutics, Inc. has received a delisting notice from Nasdaq due to its common stock trading below $1.00 for 30 consecutive business days and is ineligible for the standard cure period, prompting the company to appeal the decision.

Summary

• Zyversa Therapeutics, Inc. received a Minimum Bid Price Deficiency Letter from The Nasdaq Capital Market Stock Exchange (Nasdaq) on May 27, 2025.
• The company's common stock had a closing bid price of less than $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• Zyversa is not eligible for the customary 180-calendar day cure period under Listing Rule 5810(c)(3)(A)(iv) due to prior reverse stock splits.
• The company effected a 1-for-35 reverse stock split on December 4, 2023, and a 1-for-10 reverse stock split on April 24, 2024, resulting in a cumulative ratio of 250 shares or more to one over the prior two-year period.
• Unless an appeal is requested by 4:00 p.m. Eastern Time on June 3, 2025, the company's securities will be delisted from the Nasdaq Capital Market on June 5, 2025.
• The company intends to appeal the Staff's determination and timely request a hearing before the hearings panel, which will stay any suspension or delisting action pending a decision.

Sentiment

Score: 2

Explanation: The company received a delisting notice from Nasdaq and is not eligible for the standard cure period, indicating severe non-compliance issues and immediate threat to its listing. While an appeal is planned, the outcome is uncertain, posing significant risk to shareholders.

Positives

• The Company intends to appeal the Staff's determination and timely request a hearing before the Nasdaq hearings panel.
• Requesting a hearing will stay any suspension or delisting action pending a decision by the Panel.

Negatives

• Received a delisting notice from Nasdaq for failing to maintain a minimum bid price of $1.00 for 30 consecutive business days.
• The Company is not eligible for the standard 180-calendar day cure period due to prior reverse stock splits (1-for-35 on December 4, 2023, and 1-for-10 on April 24, 2024).
• Securities face delisting from the Nasdaq Capital Market on June 5, 2025, if an appeal is not filed by June 3, 2025.
• There is no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market Exchange.

Risks

• Inability to regain compliance with Nasdaq's continued listing requirements, including the $1.00 minimum bid price rule.
• Potential delisting of shares from the Nasdaq Capital Market.
• Failure to timely file the request for a hearing before the Panel.
• Uncertainty regarding the outcome of the appeal process before the Nasdaq hearings panel.

Future Outlook

The company intends to appeal Nasdaq's delisting determination and request a hearing, which would temporarily stay the delisting action. However, there is no guarantee that the company will ultimately regain compliance with Nasdaq's listing requirements.

Management Comments

• "The Company intends to appeal the Staff's determination and timely request a hearing before the hearings panel (the Panel)."
• "There can be no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market Exchange."

Industry Context

This announcement highlights the strict compliance requirements of major stock exchanges like Nasdaq, particularly the minimum bid price rule. Companies, especially smaller ones or those in early development stages, often face challenges maintaining share price above the minimum threshold, sometimes resorting to reverse stock splits which can have negative investor perception and, as seen here, impact eligibility for compliance extensions.

Stakeholder Impact

• Shareholders: Potential loss of liquidity and market access if delisted from Nasdaq, significant negative impact on share price, increased volatility, and potential difficulty in trading shares.
• Company Operations: Increased administrative burden and costs associated with the appeal process and potential alternative listing venues if delisted.

Next Steps

• The Company must request an appeal by 4:00 p.m. Eastern Time on June 3, 2025.
• The Company intends to request a hearing before the Nasdaq hearings panel.
• The Panel will make a decision regarding the Company's continued listing.

Key Dates

Recommendation

Keywords

Zyversa Therapeutics, ZVSA, Nasdaq, delisting, minimum bid price, reverse stock split, stock exchange, compliance, 8-K, SEC filing, capital market